# US 2017/0281633 A1 · Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281633 A1
- Document ID: US20170281633A1
- Status: Published application
- Kind: A1
- Application number: 15/475,899
- Filed: 2017-03-31
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Signal Pharmaceuticals, LLC
- Applicants: Signal Pharmaceuticals, LLC
- Inventors: John F. Boylan; Gordon L. Bray; Ellen Filvaroff; Robert Hubbard; David Mikolon; Heather Raymon; Tao Shi; Tam M. Tran; Toshiya Tsuji; Lilly L. Wong; Shuichan Xu; Dan Zhu
- Web page: https://patentgrep.com/patent/US20170281633A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.

## Claims

### Claim 1

A method for treating or preventing a solid tumor or a hematological cancer, the method comprising administering to a subject having the solid tumor or hematological cancer an effective amount of Aminopurine Compound of formula (I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof,
wherein:
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
R2 is H or substituted or unsubstituted C1-3 alkyl; and
R3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C1-3 alkyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is selected from Table 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the solid tumor is melanoma,
colorectal cancer, stomach cancer, head and neck cancer, thyroid cancer, bladder cancer, CNS cancer, lung cancer, pancreatic cancer, or soft tissue cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is bladder cancer, breast cancer, CNS cancer, colon cancer, gastrointestinal cancer, endocrine cancer, female genitoureal cancer, head and neck cancer, hematopoietic cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreas cancer, prostate cancer, or soft tissue cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is glioma, neuroblastoma, stomach cancer, thyroid cancer, adrenal gland cancer, cancer of the uterus, cervix, ovary clear cell, or vulva, leukemia, myeloma, NSCLC, SCLC, sarcoma or osteosarcoma

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is colorectal cancer (CRC), melanoma, gastric cancer, hepatocellular carcinoma (HCC), lung cancer, pancreatic cancer, leukemia, or multiple myeloma.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is a cancer expressing PD-L1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the PD-L1 expressing cancer is melanoma, lung cancer, renal cell carcinoma (RCC), or HCC.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is characterized by a BRAF mutation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cancer characterized by a BRAF mutation is CRC, thyroid cancer, melanoma or lung cancer.

### Claim 12 (depends on 10)

The method of claim 10, wherein the BRAF mutation is BRAF V600E.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is characterized by an NRAS mutation.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer characterized by an NRAS mutation is melanoma.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is characterized by a KRAS mutation.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer characterized by a KRAS mutation is CRC, pancreas cancer or lung cancer.

### Claim 17

A method for treating or preventing a cancer characterized by a beta-catenin mutation, the method comprising administering to a subject having cancer characterized by a beta-catenin mutation an effective amount of an Aminopurine Compound of formula (I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof,
wherein:
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
R2 is H or substituted or unsubstituted C1-3 alkyl; and
R3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C1-3 alkyl.

### Claim 18 (depends on 17)

The method of claim 17, wherein the beta-catenin mutation is one or more of beta-catenin S33Y, G34E, S45del, or S33C.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cancer characterized by a beta-catenin mutation is CRC, stomach cancer, HCC or sarcoma.

### Claim 20

A method for treating or preventing a cancer characterized by an activated beta-catenin pathway, the method comprising administering to a subject having cancer characterized by an activated beta-catenin pathway an effective amount of an Aminopurine Compound of formula (I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, or isotopologue thereof,
wherein:
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
R2 is H or substituted or unsubstituted C1-3 alkyl; and
R3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C1-3 alkyl.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer characterized by the beta-catenin pathway is CRC, stomach cancer, hepatocellular carcinoma or sarcoma.

### Claim 22 (depends on 17)

The method of claim 17, wherein the cancer is hepatocellular carcinoma, gastric cancer, melanoma.

### Claim 23 (depends on 22)

The method of claim 22, wherein the HCC is characterized by a beta-catenin mutation and/or increased YAP expression.

### Claim 24 (depends on 17)

The method of claim 17, further comprising an EGFR mutation or increased EGFR activity.

### Claim 25 (depends on 24)

The method of claim 24, wherein the EGFR mutation is one or more of EGFR E282K, G719S, P753S, or V1011M.

### Claim 26 (depends on 17)

The method of claim 17, further comprising a BRAF mutation.

### Claim 27 (depends on 26)

The method of claim 26, wherein the BRAF mutation comprises a BRAF V600E, BRAF T119S, or BRAF G596R mutation.

### Claim at position 28

-29. (canceled)

### Claim 30

A method for modulating the levels of a biomarker in a subject having a cancer, the method comprising administering to the subject an effective amount of a Aminopurine Compound of formula (I):
or a pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, and isotopologue thereof,
wherein:
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;
R2 is H or substituted or unsubstituted C1-3 alkyl; and
R3 is phenyl, substituted with one or more halogen, optionally further substituted with one or more substituents independently selected from substituted or unsubstituted C1-3 alkyl, CN, and —OR′, wherein each R′ is independently substituted or unsubstituted C1-3 alkyl.

### Claim 31 (depends on 30)

The method of claim 30, wherein the modulation of the biomarker is assessed in a biological sample of the subject, selected from circulating blood, skin biopsies, tumor biopsies, circulating tumor cells, hair, or urine.

### Claim 32 (depends on 30)

The method of claim 30, wherein the biomarker is ERK, RSK1, DUSP4, DUSP5, DUSP6, BMF, EFNA1, EGR1, ETV5, FOS, FOSL1, GJA1, IL-8, cMyc, Cyclin D1, YAP, SPRY2, SPRY4, Axin2, CTGF, AREG, CYR61, CXCL1, HAS2, HES1, MAFF, CITED2, ELF3, or PD-L1.

### Claim 33 (depends on 30)

The method of claim 30, wherein the modulation is measured by measurement of the reduction of phosphorylation levels of one or more of ERK and RSK1.

### Claim 34 (depends on 27)

The method of claim 27, wherein the modulation is measured by measurement of the reduction in mRNA or protein expression levels of one or more of DUSP4, DUSP5, DUSP6, EGR1, ETV5, FOS, FOSL1, IL-8, cMyc, Cyclin D1, YAP, SPRY2, SPRY4, Axin2, CTGF, AREG, CYR61, CXCL1, HAS2, HES1, and MAFF.

### Claim 35 (depends on 30)

The method of claim 30, wherein the modulation is measured by measurement of the increase in mRNA or protein expression levels of one or more of BMF, EFNA1, CITED2, and ELF3.

### Claim 36 (depends on 1)

The method of claim 1, wherein the Aminopurine Compounds is administered as a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.

### Claim 37 (depends on 17)

The method of claim 17, wherein the Aminopurine Compounds is administered as a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.

### Claim 38 (depends on 30)

The method of claim 30, wherein the Aminopurine Compounds is administered as a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient.

### Claim 39 (depends on 20)

The method of claim 20, wherein the cancer is CRC, stomach cancer, hepatocellular carcinoma or sarcoma.

### Claim 40 (depends on 20)

The method of claim 20, wherein the cancer is hepatocellular carcinoma, gastric cancer, melanoma.

### Claim 41 (depends on 20)

The method of claim 20, further comprising an EGFR mutation or increased EGFR activity.

### Claim 42 (depends on 41)

The method of claim 41, wherein the EGFR mutation is one or more of EGFR E282K, G719S, P753S, or V1011M.

### Claim 43 (depends on 20)

The method of claim 20, further comprising a BRAF mutation.

### Claim 44 (depends on 43)

The method of claim 43, wherein the BRAF mutation comprises a BRAF V600E, BRAF T119S, or BRAF G596R mutation.
